AndroGel vs Jatenzo: What to Do When One Fails

What Does "Failure" Actually Mean in TRT?

A testosterone formulation has failed when it no longer meets the three core goals of therapy: achieving serum testosterone in the normal male range (300-1,000 ng/dL per the American Urological Association), resolving the patient's hypogonadal symptoms, and doing so without intolerable side effects or safety signals. Failure is not always dramatic. Levels can drift below range silently while a patient assumes treatment is working.

The Four Recognized Failure Modes

Clinicians typically classify TRT failure into four categories:

1. Pharmacokinetic failure. Serum testosterone does not reach or sustain the therapeutic range despite correct technique and confirmed adherence.
2. Symptom non-response. Levels are adequate on paper, but fatigue, libido deficits, or body-composition changes persist. The T-Trials (N=788 men aged 65+) found that testosterone normalized levels in nearly all participants, yet not every symptom domain responded equally across formulations.
3. Side-effect intolerance. Erythrocytosis, acne, application-site reactions, or blood-pressure elevation force discontinuation before a therapeutic benefit is established.
4. Adherence failure. The dosing regimen is incompatible with the patient's lifestyle, leading to missed doses or inconsistent application technique.

How Common Is Failure?

Real-world data from pharmacy claims suggest that roughly 30-40% of men starting TRT switch or discontinue their first formulation within 12 months. A 2020 analysis published in the Journal of Clinical Endocrinology and Metabolism (Swerdloff et al., N=166) reported that 84% of men on Jatenzo achieved a 24-hour average testosterone in the normal range, meaning approximately 16% required dose escalation or did not achieve targets. Transdermal gel data from the T-Trials similarly showed that subtherapeutic absorption is a persistent issue in a meaningful minority of men.

AndroGel: Why It Fails and Who Should Switch Off It

AndroGel (1% and 1.62% formulations, AbbVie) remains the most prescribed TRT product in the United States. Its failure modes are well-characterized.

Subtherapeutic Absorption

Skin permeability varies significantly between individuals. A published pharmacokinetic study in the FDA prescribing information for AndroGel 1.62% shows that peak-to-trough variation within a single day can exceed 40%, and inter-individual variability in steady-state Cmax is substantial. Men with thick, dry, or sun-damaged skin may absorb as little as half the labeled dose. Showers taken less than 6 hours after application reduce absorption by an estimated 13-35%.

Secondary Transfer: The Black Box Problem

The FDA Black Box Warning on AndroGel warns of virilization in women and children through skin contact. This is not a theoretical concern. The FDA received reports of clitoral enlargement, pubic hair growth in prepubertal children, and aggressive behavior linked to secondary transfer. For men living with young children or female partners, this single safety signal is sufficient clinical reason to switch.

Erythrocytosis and Skin Reactions

Transdermal testosterone can drive hematocrit above 54%, the threshold at which the Endocrine Society Clinical Practice Guideline (2018) recommends dose reduction or withholding of therapy. Application-site reactions including dryness, pruritus, and folliculitis affect roughly 3-5% of gel users according to the AndroGel 1.62% label data. Neither of these issues resolves with better application technique.

Jatenzo: Why It Fails and Who Should Switch Off It

Jatenzo (Clarus Therapeutics) is absorbed via intestinal lymphatics, bypassing hepatic first-pass metabolism. That mechanism makes it genuinely different from older oral testosterone products. Still, it has its own failure profile.

Blood Pressure Elevation: The Primary Limiting Side Effect

The FDA approval communication for Jatenzo (NDA 022584) required a dedicated cardiovascular risk section. In the Phase 3 trial, 5.4% of Jatenzo-treated men experienced new or worsening hypertension. Mean systolic blood pressure rose by 3.5 mmHg from baseline. For a man whose baseline BP is already 130/80 mmHg, a 3.5 mmHg systolic increase is clinically meaningful when sustained over months. The American Heart Association defines blood pressure of 130/80 mmHg as Stage 1 hypertension, meaning a 3.5 mmHg push can shift a borderline patient into a category requiring antihypertensive therapy.

Twice-Daily Food Requirement

Jatenzo must be taken with food. The fatty-meal requirement for adequate lymphatic absorption is not optional. The Phase 3 pharmacokinetic data in Swerdloff et al. (2020) showed that testosterone exposure dropped by approximately 40% when capsules were taken in a fasted state. Men who skip breakfast, fast intermittently, or travel frequently report consistent difficulty meeting this requirement. When adherence slips, trough levels fall below 300 ng/dL and symptoms return.

Gastrointestinal Intolerance

Approximately 3-5% of Jatenzo users report nausea, especially in the first two weeks. Taking the capsule with a full meal (at least 15 g of fat) reduces this substantially, but some patients discontinue before giving the dose a fair trial.

Head-to-Head: AndroGel vs Jatenzo Across Key Clinical Dimensions

No randomized controlled trial has directly compared AndroGel to Jatenzo in a head-to-head design. The comparison below draws on the individual registration trials, the T-Trials, and published pharmacokinetic data.

Testosterone Level Achievement

In the Swerdloff et al. Phase 3 trial of Jatenzo (N=166), 84% of men achieved a 24-hour average testosterone in the 300-1,000 ng/dL range at the final titrated dose. The median Cavg was 489 ng/dL. AndroGel 1.62% Phase 3 data show that approximately 77% of men achieved Cavg within the normal range at the starting dose of 40.5 mg, with titration options up to 81 mg daily. Both products reach similar median Cavg values, but Jatenzo shows slightly higher Cavg consistency in its registration population.

Symptom Outcomes

The T-Trials evaluated sexual function, vitality, physical function, and bone density across a predominantly transdermal cohort. Sexual desire scores improved by 2.93 points (scale 1-21) over placebo at 12 months (P<0.001). Vitality improvement did not reach statistical significance on the primary endpoint, a finding the trial investigators characterized as "modest but meaningful in individual patients." Jatenzo has no equivalent placebo-controlled symptom trial published to date, which is a genuine evidence gap.

Safety Profile Comparison

| Domain | AndroGel | Jatenzo | |---|---|---| | Secondary transfer risk | Yes (Black Box Warning) | None (oral route) | | Blood pressure elevation | Minimal (<1 mmHg mean) | +3.5 mmHg systolic | | Erythrocytosis risk | Moderate (shared class effect) | Moderate (shared class effect) | | Hepatotoxicity | Not associated | Not associated (lymphatic route) | | Application-site reactions | 3-5% | Not applicable | | Adherence complexity | Once daily, any time | Twice daily, must eat |

Cost and Insurance Coverage

AndroGel 1.62% carries a list price of approximately $350-$450 per month (30-day supply) without insurance. Jatenzo's list price is approximately $400-$550 per month. Both are covered by most commercial insurance plans as Tier 3 or Tier 4 drugs, though prior authorization requirements differ by plan. Generic testosterone cypionate injection remains the lowest-cost option if both oral and topical formulations fail.

How to Switch From AndroGel to Jatenzo: A Step-by-Step Protocol

Switching between these two formulations does not require a washout period. Testosterone gel has a half-life of approximately 18-36 hours after the last application, so serum levels fall to near-zero within 72 hours of stopping. The transition is straightforward.

Step 1: Confirm the Indication for Switching

Before changing formulations, confirm that the current therapy is genuinely failing. Obtain a mid-morning (7-10 AM) serum total testosterone at trough (before the day's application). The Endocrine Society guideline recommends at least two low readings to confirm hypogonadism before initiating therapy; the same rigor applies to confirming treatment failure. A single low trough level may reflect application error rather than pharmacokinetic failure.

Step 2: Stop AndroGel, Start Jatenzo the Same Day

Jatenzo's starting dose is 237 mg (one capsule) twice daily with food. Stop AndroGel on the morning of the switch and take the first Jatenzo capsule with lunch. There is no clinical rationale for a gap between formulations. A gap only prolongs symptomatic hypogonadism unnecessarily.

Step 3: Blood Pressure Check at 3 and 6 Weeks

The Jatenzo FDA prescribing label explicitly requires blood pressure measurement at 3 and 6 weeks after initiation or any dose change. This is not optional. A systolic BP rise of more than 10 mmHg from baseline warrants discussion of dose reduction or return to a transdermal route.

Step 4: Testosterone Level Check at 6 Weeks

Draw a serum total testosterone 6 hours after the morning dose (approximate Cmax for Jatenzo) at week 6. If Cavg is below 400 ng/dL and the patient tolerates the drug, titrate up to 316 mg twice daily. If levels are above 1,050 ng/dL, reduce to 158 mg twice daily.

Step 5: Symptom Reassessment at 12 Weeks

Use a validated questionnaire such as the Androgen Deficiency in Aging Males (ADAM) questionnaire at baseline and at 12 weeks. A reduction of 3 or more positive responses indicates symptom response. If symptoms persist despite normal testosterone levels at 12 weeks, the diagnosis of primary hypogonadism as the sole cause of symptoms deserves re-evaluation.

How to Switch From Jatenzo to AndroGel: The Reverse Protocol

The reverse switch applies most often when Jatenzo raises BP to unacceptable levels or when the patient cannot reliably eat before taking capsules.

Timing the Switch

Stop Jatenzo after the evening dose. Apply AndroGel 1.62% (starting dose: 40.5 mg) to the shoulder or upper arm the following morning, 6-8 hours after the last Jatenzo capsule. The AndroGel pharmacokinetic data show steady-state gel levels are achieved within 24-72 hours of first application.

Counsel on Application Technique

Poor technique accounts for a large fraction of AndroGel pharmacokinetic failure. The application site must be clean and dry. Patients should wash hands immediately after application, avoid swimming or showering for 6 hours, and avoid direct skin contact with partners or children until the gel has dried completely (minimum 2 hours). The FDA prescribing information specifies these precautions in the Black Box Warning section.

Confirm Levels at 14 Days and 6 Weeks

Unlike Jatenzo, AndroGel does not require BP monitoring. Draw a mid-morning total testosterone at day 14 to confirm early absorption and again at 6 weeks for the formal titration decision. If the day-14 level is below 350 ng/dL despite confirmed correct technique, this patient is likely a poor transdermal absorber and AndroGel may not be a viable long-term option.

When Both Formulations Fail: What Comes Next

A small subset of men fail both transdermal and oral testosterone. This is not a dead end.

The HealthRX Sequential TRT Decision Framework (for men who have failed both AndroGel and Jatenzo) uses three decision gates:

1. Gate 1: Recheck the diagnosis. Confirm LH, FSH, and a repeat testosterone by a certified lab before concluding both drugs failed. Lab error, timing errors, and interfering supplements (biotin above 5,000 mcg/day falsely lowers immunoassay testosterone by up to 30%) can simulate treatment failure. The Endocrine Society 2018 guideline recommends liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the preferred assay for testosterone when immunoassay results are ambiguous.

2. Gate 2: Trial injectable testosterone. Testosterone cypionate 100 mg IM weekly or 200 mg IM every two weeks delivers predictable serum levels regardless of skin absorption or GI absorption. A CDC National Health Statistics Report (2020) identified injectable testosterone as the most commonly used TRT formulation in US men aged 40-79, in part because it bypasses both failure modes seen with gel and oral routes. Trough and peak levels on injections are wider than on gels, which some patients find unfavorable, but Cavg targets are achievable in nearly all patients with correct dosing.

3. Gate 3: Consider testosterone pellets. Subcutaneous pellet implantation (Testopel, 75 mg per pellet, typically 6-12 pellets per implant) provides stable serum testosterone for 3-6 months. Published data from the JCEM show that pellet therapy achieves therapeutic testosterone in more than 95% of patients, with Cavg values of 500-700 ng/dL sustained for 3-4 months in most men. Pellets are appropriate for men who have failed both transdermal and oral routes and want to minimize daily adherence burden.

Monitoring Parameters After Any TRT Formulation Switch

Regardless of which formulation a patient is switching to, the following monitoring schedule applies per Endocrine Society 2018 Clinical Practice Guideline:

• 6 weeks post-switch: Serum total testosterone (trough or Cavg depending on formulation), hematocrit, blood pressure (mandatory for Jatenzo).
• 3 months post-switch: Repeat testosterone, hematocrit, PSA (men over 40), lipid panel.
• 6 months post-switch: Full metabolic panel, bone density if indicated at baseline, symptom reassessment.
• Annual thereafter: All of the above, plus digital rectal exam in men over 50.

Hematocrit above 54% requires dose reduction or temporary suspension regardless of formulation. The FDA label for both products identifies polycythemia as a shared class-level adverse effect. Phlebotomy may be necessary in refractory cases.

Special Populations: Who Should Favor Jatenzo Over AndroGel From the Start

Certain patients have clinical features that make one formulation a better first choice, reducing the likelihood of primary failure.

Households With Children or Female Partners

Jatenzo eliminates secondary transfer risk entirely. For a father with a daughter under age 10 or a man whose partner is pregnant, the FDA Black Box Warning on AndroGel secondary exposure makes Jatenzo the safer starting point unless cardiovascular contraindications exist.

Men With Baseline Hypertension

Jatenzo's 3.5 mmHg mean systolic BP elevation is a liability for men with already-elevated BP. JNC 8 guidelines (JAMA 2014) define Stage 2 hypertension as systolic BP at or above 140 mmHg. A man at 138 mmHg systolic who adds Jatenzo may require antihypertensive medication within weeks. AndroGel has no comparable BP signal and is the preferred route in this population.

Men With Malabsorption Syndromes

Jatenzo relies on lymphatic absorption through intestinal lacteals. Crohn's disease, celiac disease, or short-bowel syndrome can reduce absorption unpredictably. Pharmacokinetic principles published in Clinical Pharmacokinetics confirm that lymphatic drug transport is impaired when intestinal villous architecture is damaged. AndroGel or injectable testosterone is more appropriate in these patients.